Abstract
Background: Benefitting from the emerging role of comprehensive genomic profiling in the era of precision medicine, genomic aberrations (amplification, mutation and fusion) of fibroblast growth factor (FGF) receptor (FGFR) are frequently found in multiple solid tumors. FGFR selective inhibitors targeting these alterations showed inspiring clinical benefits. Currently three FGFR inhibitors have been approved as monotherapy to treat locally advanced or metastatic urothelial carcinoma with FGFR2/3 alterations (erdafitinib) and unresectable cholangiocarcinoma with FGFR2 fusions (pemigatinib and infigratinib) through accelerated approval process.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
